English
Philippe Rochigneux
383 posts
Philippe Rochigneux
@prochigneux
Medical Oncologist @paoli_calmettes (Marseille, France).
Katılım Haziran 2009
72 Takip Edilen71 Takipçiler
Dr Beaufils ans Dr Bruyat presenting #Immunotherapy data at the annual #ESMO24 meeting. Congratulations to both ! 👏👏👏 @paoli_calmettes @crcm_marseille @prochigneux @ProfAnthoG
English
Philippe Rochigneux retweetledi
Philippe Rochigneux retweetledi
#GabrielAttal aurait donc décidé d’augmenter les places en 2eme année de médecine à 16000 en 2027. Très bonne idée. Mais il faut en même temps :
-augmenter les moyens des facs, des hôpitaux d’accueil et le nb d’enseignants
-conditionner dès le debut l’exercice ultérieur
Gabriel Attal@GabrielAttal
Nous voulons garder le meilleur et le plus beau système de santé au monde. Et nous allons y arriver. Pour continuer de se battre pour lui, nous allons grâce à ces nouvelles mesures reconquérir 15 à 20 millions de rendez-vous médicaux chaque année et simplifier le quotidien de nos soignants.
Français
@jitcancer @MyeLau_Gorvel great news ! congrats Mathilde Beaufils and all the team @TumImmuno_CRCM !
English
Philippe Rochigneux retweetledi
New #JITC article: Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records bit.ly/3QoDYYA @MyeLau_Gorvel @prochigneux
English
@jitcancer @MyeLau_Gorvel great news ! congrats Mathilde Beaufils and all the team!
English
Philippe Rochigneux retweetledi
Fantastic discussion of amazing plenary data @asco23 by fabulous @bensolomon1 #egfrmutant #NSCLC @PeterMacCC @PeterMacRes
Christian Rolfo@ChristianRolfo
Congrats @bensolomon1 for the great discussion of the unprecedented OS data of ADAURA. Important to guarantee access to medication for our patients around the world and TESTING! Great slide by @jillfeldman4 on toxicity considerations. #ASCO23 @EGFRResisters @asco @isliquidbiopsy
Chicago, IL 🇺🇸 English
Philippe Rochigneux retweetledi
So great to see this out after #ESMO22! No doubt about it: neoadjuvant is here to stay! Congrats @DrSapnaPatel @EladSharonMD and team! Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma | NEJM nejm.org/doi/full/10.10…
English
Delighted to have this PhD paper out in Clinical Cancer Reasearch! Immune predictors of Pembro efficacy in NSCLC. Great collab between Marseillle @paoli_calmettes @TumImmuno_CRCM and UCLA @dgsomucla. aacrjournals.org/clincancerres/…
English
Philippe Rochigneux retweetledi
NEOpredict-Lung @myESMO: exploring the feasibility & efficacy of targeting PD-1 and LAG-3 prior to resection --> R0 resection rate was 97%. Complete or major histopathological response 30% in the combination arm @OncoAlert #ESMO2022
English
Philippe Rochigneux retweetledi
One of THE BEST PRESIDENTIAL Symposium @myESMO "What is the driver of a driver-mutant NSCLC"? by Dr. Swanton and an excellent discussion by Dr. Delaloge
-> PM 2.5 ↑es the risk of multiple tumors
-> PM 2.5 associated with ↑ed risk of EGFRm NSCLC #LCSM @OncoAlert #ESMO22
English
Philippe Rochigneux retweetledi
Always impressed by the rapidity of tumor regression after only 1 injection of Datopotamab deruxtecan (ADC-anti Trop2) (ICARUS-Lung01trial @GustaveRoussy ). NSCLC with an EGFRmut (Del19) after Osimertinib then Platinum-Pemetrexed-Pembrolizumab… @CICThoraciques
English
Philippe Rochigneux retweetledi
Out in @NEJM overall survival data from #KEYNOTE355 trial showing benefit of adding #pembrolizumab to chemotherapy as 1st-line treatment in advanced #PDL1+ triple-negative #BreastCancer: congrats super @JavierCortesMD @hoperugo et al!
@OncoAlert #bcsm
nejm.org/doi/full/10.10…
Genoa, Liguria 🇮🇹 English
Philippe Rochigneux retweetledi
